FuturHealth files Chapter 11 and puts itself up for sale
Also in this issue: GLP-1 cash-pay median fell to $299 in October
Forwarded this? Get it weekday mornings.
Take. FuturHealth bought its GLP-1 growth with radio ads. The ads stopped paying once a Novo lawsuit ended its compounded marketing. Expect rivals to bid for its patients, which makes paid search more expensive. We'd put next quarter's budget into referrals and retention.
FuturHealth, the San Diego weight-loss telehealth company, filed for Chapter 11 in Delaware on Sunday, Nov. 1, according to the court docket. Judge J. Kate Stickles approved its first-day motions on Tuesday. Law360 reported that the judge let FuturHealth draw $2 million of a $5 million debtor-in-possession loan.
The filings describe an ad bet that went wrong, per Bondoro. FuturHealth signed a roughly $14 million iHeartMedia ad deal that "failed to produce the expected return." It paid more than $4 million in cash in the first half of 2025. The rest became a secured loan of about $9 million. FuturHealth stopped marketing compounded GLP-1s in August 2025 after Novo Nordisk sued. That case has since settled.
FuturHealth cut non-marketing costs about 42% from January to July 2026. Merchant cash advance and iHeart payments still ran near $500,000 a month, per Bondoro. Hilco is running a sale. The lender, Twelve Bridge Capital, holds back the last $4 million until a final order and a stalking-horse bid. iHeartMedia is owed about $8 million.
| When | Who | Status |
|---|---|---|
| Tue, Nov. 24 | Objection deadline for final financing order | Upcoming |
| Tue, Dec. 1, 3:00 PM ET | Second-day hearing, Judge Stickles | Upcoming |
The Signal
Telehealth
GLP-1 cash-pay median falls to $299 a month
The median U.S. GLP-1 telehealth program charged $299 a month in October across 33 programs, per GLP Chart's monthly price index. The 20 programs priced in both September and October held at $333. The cheapest compounded semaglutide was $59 a month for the drug alone. GLP Chart gets paid on some of its links. RxPickr reported that MEDVi now says refills are "locked in" at $199, down from $299 in October. Price cuts on renewals hit lifetime value harder than intro offers do. We'd put a reason for the gap on the page of any program priced at $333 or more. Patients won't guess it.
Coverage
Novo sells Wegovy to employers through Andel
Andel will offer the Wegovy pill and injection to the employers on its marketplace, per a press release. AJMC reported that the lowest-dose self-pay price is $149 a month for the pill and $199 for the injection. That puts employer-funded brand drug at $149 against compounded programs for the same patients.
Patient Demand
PeterMD lists TRT at $79 a month on a yearly plan
PeterMD lists injectable testosterone at $79 a month on a 12-month plan. Month to month costs $139. We'd quote the monthly price first.
Wire
- Hims & Hers reports third-quarter results next Monday after the close, with a call at 5:00 PM ET, per its investor site.
- Apollo Wellness Centers released a video on its Doc-Rx turnkey clinic platform, per an AccessNewswire release. It gave no pricing.
Optimized Daily Report is business news for clinic operators. Not medical, legal, or investment advice. Company claims are the company's.